文献速递抗栓抗凝管理药物不良反应与药物警戒

房颤成人患者直接口服抗凝药的真实世界依从性与持续性

Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.
PubMed 文献 · Pharmacotherapy · 2017-09-06

本研究基于Truven Health MarketScan数据库(2009-2013),纳入66,090例新启用DOAC的房颤患者,比较抗凝初治与经治患者的依从性和持续性。结果显示,初治患者6个月和12个月的平均PDC分别为72.3%和63.7%,经治患者分别为83.3%和79.9%(均p<0.001);持续性同样随时间下降且初治患者更低。

要点

  • 初治患者6个月和12个月平均PDC为72.3%和63.7%,均低于经治患者的83.3%和79.9%。
  • 初治患者6个月和12个月持续性为59.3%和31.6%,经治患者为76.3%和50.2%。
  • 高龄和合并用药数量多与较高依从性相关,合并症多和初治状态与较低依从性相关。

核心结论

  • DOAC依从性和持续性随时间下降,且初治患者在各时间点均低于经治患者。

研究设计与样本

  • 回顾性队列研究,数据来自Truven Health MarketScan Commercial和Medicare Supplemental数据库(2009-2013)。
  • 纳入66,090例新启用DOAC且前后至少6个月连续参保的房颤患者。

主要发现

  • 初治患者46.6%(n=30,826),经治患者53.4%(n=35,264),年龄分别为66.9±12.7岁和70.4±11.4岁(p<0.001)。
  • 74.5%(n=49,210)患者起始使用达比加群。
  • 6个月和12个月平均PDC:初治72.3% vs 经治83.3%(p<0.001),初治63.7% vs 经治79.9%(p<0.001)。
  • 6个月和12个月持续性:初治59.3% vs 经治76.3%(p<0.0001),初治31.6% vs 经治50.2%(p<0.0001)。
  • 较高依从性预测因素为高龄和合并用药数量多;较低依从性预测因素为合并症多和初治状态。

临床怎么用

  • 对DOAC初治的房颤患者应加强患者教育和长期抗凝管理,以改善依从性和持续性。

局限性

  • 研究为回顾性数据库分析,依从性基于处方填充数据而非实际服药。
  • 未探讨初治与经治患者依从性差异的原因及对临床结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence of adherence and persistence patterns in anticoagulation (AC) therapy comparing treatment-naïve and non-naïve patients is lacking. The objective of this study was to evaluate patterns of medication adherence and persistence in a real-world setting among AC-naïve and AC-experienced patients with atrial fibrillation (AF) who were treated with direct oral anticoagulants (DOACs). METHODS: AF patients newly initiating a DOAC with a minimum of 6 months of continuous health plan enrollment pre and postindex date (first DOAC prescription) were identified from the Truven Health MarketScan Commercial and Medicare Supplemental databases (2009-2013). DOAC adherence (proportion of days covered [PDC]), persistence, and predictors of adherence were assessed at 6 and 12 months postindex. RESULTS: Of 66,090 AF patients included, 46.6% (n=30,826) were AC naïve and 53.4% (n=35,264) were AC experienced (age: 66.9 ± 12.7 vs 70.4 ± 11.4 yrs, p<0.001; male: n=19,132 [62.1%] vs n=21,691 [61.5%], p=0.14, respectively). A majority of patients received dabigatran as their index DOAC (n=49,210; 74.5%). The mean PDC in AC-naïve versus AC-experienced patients at 6 and 12 months of follow-up was 72.3% versus 83.3% (p<0.001) and 63.7% versus 79.9% (p<0.001), respectively. Persistence with DOAC therapy in AC-naïve and AC-experienced patients at 6 and 12 months ranged from 59.3% and 76.3% (p<0.0001) to 31.6% and 50.2% (p<0.0001), respectively. Predictors of higher DOAC adherence were older age and higher number of concomitant medications. Predictors of lower adherence were higher number of comorbidities and AC-naïve user status. CONCLUSION: Medication adherence and persistence with DOACs declined over time and both were suboptimal and lower (at 6 and 12 mo postindex) in AC-naïve compared to AC-experienced patients. These findings can help target future strategies or interventions for patient education and long-term AC management especially in those patients naïve to DOAC therapy. Future investigation should examine potential reasons for differences in DOAC adherence and persistence between AC-experienced versus AC-naïve patients and the implications for patient outcomes.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Manzoor BS, Lee TA, Sharp LK, et al. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. Pharmacotherapy. 2017. PMID: 28730619. doi:10.1002/phar.1989

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。